Brain Tumor Drug Developer Celldex Prices $174M Offering
By Zachary Zagger ( February 26, 2015, 8:06 PM EST) -- Celldex Therapeutics Inc. is looking to raise $174 million in an underwritten stock offering that the biotechnology company priced at $24 per share Thursday as the company looks to capitalize on the U.S. Food and Drug Administration greenlighting its brain tumor therapy....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.